NCT06556277Completed
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake: a Double-blind, Randomized, Placebo-controlled, Cross-over Study
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The investigator aim to understand whether food-induced glucocorticoids influence fat mass in overweight and obese people. In a randomized, cross-over study, 23 overweight and obese volunteers will receive a block and replace therapy that mimics physiological glucocorticoid (GC) rhythm (metyrapone plus hydrocortisone) or placebo. Participants will undergo two identical overfeeding periods with each treatment. With the block and replace therapy food-induced GC peak will be suppressed. Metabolic and immunological parameters will be compared to reveal the effects of GCs during excessive overfeeding, particularly to understand changes in body fat.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 17 Jul 2024
- Start date
- 1 Sept 2024
- Primary completion date
- 25 Feb 2026
- Lead sponsor
- Eleonora Seelig
- Diseases
- Obesity
- NCT number
- NCT06556277
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 1 Sept 2024 to the primary completion date, 25 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intake of GLP-1 agonists or hormone therapy
- Participation in an investigational drug trial within the past two months
- Intake of any steroid-containing drugs, including topical steroids and inhalers, within 4 weeks of the study initiation
Other illness
- Any severe acute or chronic disease, including diabetes mellitus type 2
- Known allergy to metyrapone
Other
- Hypercortisolism
- Casual smoking (more than 6 cigarettes per day)
- Frequent, heavy alcohol consumption (more than 30g/day)
- Frequent, heavy caffeine consumption (more than 4 caffeinated drinks/day)
- Regular physical exercise (more than 4hrs per week)
- Shift work
- Inability or unwillingness to provide informed consent
Who the study is looking for
- Males aged 18 to 50 years
- BMI≥ 25 kg/m² with a stable weight within past three months before study initiation
Age in the registry: 18 years to 50 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.